



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48		A2	(11) International Publication Number: WO 98/01162
			(43) International Publication Date: 15 January 1998 (15.01.98)
(21) International Application Number: PCT/US97/13116		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 July 1997 (09.07.97)			
(30) Priority Data: 60/021,408 9 July 1996 (09.07.96) US			
(71) Applicant: THE JOHNS HOPKINS UNIVERSITY (US/US); 720 Rutland Avenue, Baltimore, MD 21205 (US).			
(72) Inventors: ROY, Krishnendu; Apartment 404, 3811 Canterbury Road, Baltimore, MD 21218 (US). MAO, Hai-Quan; Apartment C8, 334 Stevenson Lane, Towson, MD 21205 (US). TRUONG, Thomas; 2008 McElerry Street, Baltimore, MD 21205 (US). AUGUST, Thomas; 905 Poplar Hill Road, Baltimore, MD 21210 (US). LEONG, Kam, W.; 10242 Breconshire Road, Ellicot City, MD 21042 (US).			
(74) Agents: SHEA, Michael, J. et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).			

(54) Title: GENE DELIVERY SYSTEM

(57) Abstract

A gene delivery system is made of enzymatically degradable polymeric cation and nucleic acid (DNA or RNA) nanospheres optionally with a linking moiety or a targeting ligand attached to the surface. The delivery system can be made by a simple method of coacervation. Targeting ligands can be attached to the nanosphere directly or via a linking moiety. The linkage design allows the attachment of any molecule onto the nanosphere surface including antibodies, cell adhesion molecules, hormones and other cell-specific ligands.

Published

Without international search report and to be republished upon receipt of that report.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauntania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

GENE DELIVERY SYSTEM

This application is a continuation-in part of Serial No. 08/657,913 filed June 7, 1994, and Serial No. 60/021,408 filed July 9, 1996.

10

BACKGROUND OF THE INVENTION

15

A variety of techniques have been used to introduce foreign genes into cells. Physical methods include co-precipitation with calcium phosphate, electroporation, and particle bombardment. While these direct transfer techniques are adequate *in vitro*, they are impractical *in vivo*. Promising *in vivo* gene therapy relies on a carrier such as viral vectors or liposomes for delivery. There are still lingering safety concerns for viral vectors. Another limitation is the size of the DNA sequences, usually limited to 7-8 kb, that can be incorporated into the viral vector. Liposomes, on the other hand, have low loading level in general. In both cases, there is the issue of cell or tissue specificity for these gene delivery systems.

20

25

Controlled drug delivery has significantly improved the success of many drug therapies (Langer, R., 1990, New methods of drug delivery, *Science*, 249:1527-33; Poznansky, et al., 1984, Biological approaches to the controlled delivery of drugs: a critical review, *Pharmacol. Rev.*, 36:277-336). A major goal of drug delivery is to localize the drug to the target site. These targeted delivery systems often take the form of injectables composed of liposomes (Gregoriadis, G., 1988, *Liposomes as Drug Carriers*, New York: Wiley; Litzinger, et al., 1992, Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications, *Biochimica et Biophysica Acta.*, 1113:201-27) and microspheres made of proteins (Cummings,

5 et al., 1991, Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumor drug deposition, *Biochem. Pharm.*, 41:1849-54; Verrijik, et al.,
10 1991, Polymer-coated albumin microspheres as carriers for intravascular tumor targeting of cisplatin, *Cancer Chemother. and Pharm.*, 29:117-21; Tabata, et al.,
15 1988, Potentiation of antitumor activity of macrophages by recombinant interferon alpha A/D contained in gelatin microspheres, *Jpn. J. Cancer Res.*, 79:636-646), polysaccharides (Rongved, et al., 1991, Crossed-linked, degradable starch microspheres as carriers of paramagnetic resonance imaging: synthesis, degradation, and relaxation properties, *Carbohydrate Res.*, 145:83-92; Carter, et al., 1991, The combination of degradable starch microspheres and angiotensin II in the manipulation of drug delivery in an animal model of colorectal metastasis, *British J. Cancer*, 65:37-9), and synthetic polymers (Davis, et al., 1984, Microspheres and Drug Therapy, *Amsterdam*; Eldridge, et al., 1991, Biodegradable microspheres as a vaccine delivery system, *Molec. Immunology*, 28:287-94; Pappo, et al., 1991, Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells, *Immunology*, 73:277-80). Polymeric systems share some of the advantages of liposomal systems such as altered pharmacokinetics and biodistribution. While liposomes might have better prospects of biocompatibility and potential for fusion with cells, polymeric microspheres have more controllable release kinetics, better stability in storage, and higher drug-loading levels for some classes of compounds.

25 There is a need in the art for a DNA delivery system which can provide controlled release, is simple to make, is stable, is cost effective, has a high DNA loading level, and is relatively non-immunogenic.

SUMMARY OF THE INVENTION

30 It is an object of the invention to provide polymeric particles for delivery of DNA to cells.

It is an object of the invention to provide a method of making polymeric particles for delivery of DNA to cells.

5 It is another object of the invention to provide a method of delivering DNA to cells using polymeric particles.

10 These and other objects of the invention are provided by one or more of the embodiments described below. In one embodiment a nanosphere for gene delivery is provided. The nanosphere comprises a polymeric cation and DNA, and optionally a linking molecule or a targeting ligand is attached to the surface of said nanosphere.

15 In another embodiment of the invention a method of forming nanospheres for gene delivery is provided. The method comprises the steps of: forming nanospheres by coacervation of DNA and a polymeric cation; and optionally adhering a linking molecule or a targeting ligand to the surface of the nanospheres.

20 In yet another embodiment of the invention a method for introducing genes into cells is provided. The method comprises incubating cells to be transfected with solid nanospheres comprising a polymeric cation and DNA. Optionally a targeting ligand is attached to the nanosphere's surface. The targeting ligand binds to the surface of the cells to be transfected.

25 Thus the present invention provides the art with an attractive DNA delivery system which is simple to prepare, is cost effective, has controlled release ability, is storage stable, and is biocompatible.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Schematic diagram showing the synthesis of gelatin-DNA coacervates.

25 Figure 2. Gel electrophoresis of cDNA before and after encapsulation. (std=standard; Sup=supernatant, Pellet=nanospheres pelleted by centrifugation).

30 Figure 3. Controlled release of intact LAMP-1 cDNA was demonstrated *in vitro*. The nanospheres were cross-linked with glutaraldehyde at various glutaraldehyde concentrations then degraded with trypsin. Figure 3A shows the time course of DNA release at various glutaraldehyde-cross-linking levels. Figure 3B shows (on gels and densitometer tracing) the

5 DNA which was released from the nanospheres at various times and at various levels of glutaraldehyde-cross-linking.

10 Figure 4. Fluorescent images of U937 cells transfected by controls and LAMP-1 cDNA-loaded nanospheres (at day 3 post-transfection). Figure 4A: anti-DC44 nanospheres without cDNA; Figure 4B: calcium phosphate transfection; Figure 4C: LAMP-1 nanospheres without antibody; Figure 4D: LAMP-1 nanospheres coated with anti-CD-44 mAB. LAMP-1 expression is manifested as granules (in lysosomes) in the cells.

15 Figure 5. Flow cytometric analysis of the transfection efficiency of U937 cells by antilymphocyte function associated antigen-1 coated nanospheres and controls. The actual mean fluorescence intensity (MFI) is shown in the insert. Msp = microspheres, MRK = a mismatched anti-P-glycoprotein antibody, PLM = anti-LFA antibody.

20 Figure 6. Temporal expression of LAMP-1 in 293s cells transfected by anti-CD44 coated nanospheres.

25 Figure 7. Preparation of DNA-chitosan nanospheres by complex coacervation. Nanospheres form as a result of Na_2SO_4 induced desolvation of the polyelectrolyte complexes. Procedures or features that may help transfection efficiency, but are not necessary for transfection include: the coencapsulation of lysosomolytic agents or therapeutic agents into the nanospheres during the complex coacervation; varying the cross-linking to affect the stability of nanospheres; conjugation of ligands to the surface of the nanospheres to enhance receptor-mediated endocytosis.

30 Figure 8. The chemistry of coupling of mannose-6-phosphate to the surface of a DNA-nanosphere using carbodiimides.

Figure 9. The chemistry of coupling of folate to the surface of a DNA-nanosphere using carbodiimides.

5 Figure 10. The chemistry of coupling of transferrin to the surface of a DNA-nanosphere using carbodiimides.

10 Figure 11. The persistence of luciferase expression in HEK293 cells after transfection with DNA-chitosan nanospheres is demonstrated. 8×10^4 HEK293 cells were seeded into each well plate 24 hours before transfection, nanospheres containing 1 μg of DNA were incubated with the cells in each well for 4 hours. The cells were further incubated with fresh medium. After 5 days, the cells were passaged at 1:5 dilution every 3-7 days (indicated by an asterisk in the figure). Luciferase activities were measured at different time points.

15 Figure 12. Expression of green fluorescence protein in HEK293 cells after transfection with chitosan nanospheres containing pDI-neoGFP plasmid. 8×10^4 HEK293 cells were seeded into each well of 12 well plate 24 hours before transfection, nanospheres containing 1 mg of DNA were incubated with the cells in each well for 4 hours. The cells were further incubated with fresh medium for 3 days, trypsinized and analyzed on a FACSscan analyzer. The percentage of positive cells (transfection percentage) versus the amount of nanospheres is shown.

20 Figure 13. Transfection of HEK293 cells with mannose-6-phosphate or folate conjugated nanospheres. $8 \times$ cells were seeded into each well of a 12 well plate 24 hours before transfection. nanospheres containing 2 μg of DNA were incubated with the cells in each well for 4 hours. The cells were further incubated with fresh medium for 3 days, and luciferase expression levels were measured using a Promega luciferase assay system.

25 Figure 14. Three-phase diagram for pRE-luciferase pcDNA-chitosan coacervation at 50 mM Na₂SO₄ and 55° C. The dark shaded area shows the concentration at which the nanosphere phase can be observed. Precipitation or aggregation occurs within the light area and there is no

5 phase separation in the white area. The conditions used to prepare nanospheres are shown by the arrow. The final composition of the nanospheres are $34.65 \pm 0.95\%$ by weight of plasmid DNA and $65.35 \pm 0.95\%$ by weight of chitosan; their encapsulation efficiencies are $98 \pm 2.0\%$ and $92.7 \pm 3.7\%$, respectively.

10 Figure 15. Size distribution of chitosan-based nanospheres is shown as determined by Dynamic Light Scattering and Photon Correlation Spectroscopy. The size of the nanospheres clustered tightly between 200 and 300 nm.

15 Figure 16. Nanopshere formulation protects plasmid DNA from DNase I digestion. Naked DNA and nanospheres were both incubated with different concentrations of DNaseI for 15 min. At 37° C. The reaction was stopped with iodoacetic acid, a DNase I inhibitor. The nanospheres were then digested with chitosanase and lysozyme for 2 hours. All samples were run on an 0.08% polyacrylamide gel and stained with ethidium bromide. Lane 20 1: molecular weight markers; lane 2: plasmid; lane 3: nanospheres; lane 4: digested nanospheres; lane 5: plasmid + DNase (0.1 μ g); lane 6: nanospheres + DNase (0.1 μ g); lane 7: nanospheres + DNase + digestion; lane 8: nanopsheres + 0.5 μ g DNase; lane 9: nanospheres + 0.5 μ g DNase + 25 digestion.

25 Figure 17. Cytotoxicity of polycationic gene carriers. HEK 293 cells (4×10^4 / well) were plated in 96-well plates. Different concentrations of chitosan, poly-L-lysine and Lipofectamine 30 were added 24 hrs. later. After 48 hrs cytotoxicity was determined by an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiaollylblue)reaction assay

5 according to a standard protocol. Diamonds: chitosan; squares: poly-L-lysine; triangles: lipofectamine.

10 Figure 18. Green fluorescence protein expression in HEK 293 cells 2 days after transfection. Transfections were carried out in a 24 well plate (5×10^4 cells/well) using different amounts of nanospheres. Transfected cells were sorted after 2 days using FACscan. Ncsp 0.1 = nanospheres with 0.1 μ g DNA, Ncsp 0.5 = nanospheres with 0.5 μ g of DNA, etc. Scsp + Chlq 1 = nanospheres with chloroquine and 1 μ g of DNA.

15 Figure 19. Uptake of nanospheres in HEK 293 cells. Nanospheres were made with the luciferase plasmid and stained with TO-PRO (Molecular Probes Inc.), a cell-impermeable DNA-binding dye. Cells were washed, trypsinized at different time points after transfection and analyzed by FACscan. Cells transfected at 4° C were used as controls to account for particles bound to cell surface.

20 Figure 20. Storage stability of DNA-chitosan nanospheres and freeze-dried nanospheres. Nanospheres were made according to methods described below. PEG-conjugated nanospheres were freeze dried directly after being spun down to sucrose gradients (50%). Transfection of HEK 293 cells was performed according to the same method as before.

25 Figure 21. Chemical scheme for attaching ligands to the surface of the DNA nanospheres.

30 Figure 22. Expression of β -gal in muscle of BALB/c mice transfected with pcBLacZ gene delivered in different forms. Levels were determined at days 7 and 21 post-transfection, and the endogenous background galactosidase activity was subtracted. Values are average (n=6) + SD.

5 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

It is a discovery of the present invention that nucleic acid molecules of various chain lengths can complex with polymeric cations in aqueous conditions to form solid nanospheres ranging from submicron to microns in size. These nucleic acid-loaded nanospheres can efficiently transfect cells.

10 According to the present invention, a polymeric cation having a similar charge density to gelatin, is used to complex with nucleic acids to form nanospheres. Proteins such as tubulin, actin, cytochrome C, human serum albumin, and histones may be used as the polymeric cation. Polymeric amino acids, such as polyarginine and polylysine, may also be used, although natural proteins are preferred. Alternatively, carbohydrates such as chitosan, proteoglycan, methylcellulose, amylose, and starch can be used as the polymeric cation. Typically the polymeric cation has a molecular weight of between 5,000-1,000,000. Chitosan may be particularly useful as the polymeric cation of the present invention. Desirably sodium sulfate is used to induce the coacervation of polymeric cation and nucleic acids. Ethanol can also be used at a concentration of about 40 to 60% to induce coacervation.

15 Targeting ligands, if desired, can be directly bound to the surface of the nanosphere or can be indirectly attached using a "bridge" or "spacer". Because of the amino groups on some polysaccharides and on proteins (as provided by arginine and lysine groups of the proteins), the surface of the nanospheres can be easily derivatized for the direct coupling of targeting moieties. For example, carbo-diimides can be used as a derivatizing agent. Alternatively, spacers (linking molecules and derivatizing moieties on targeting ligands) such as avidin-biotin can be used to indirectly couple targeting ligands to the nanospheres. Biotinylated antibodies and/or other biotinylated ligands can be coupled to the avidin-coated nanosphere surface efficiently because of the high affinity of biotin ($k_a \sim 10^{15} M^{-1}$) for avidin (Hazuda, et al., 1990, Processing of precursor interleukin 1 beta and inflammatory disease, *J. Biol. Chem.*, 265:6318-22; Wilchek, et al., 1990, Introduction to avidin-biotin technology, *Methods In Enzymology*, 184:5-13). Orientation-selective attachment of IgGs can be achieved

5 by biotinylating the antibody at the oligosaccharide groups found on the F_C portion
(O'Shannessy, et al., 1984, A novel procedure for labeling immunoglobulins by
conjugation to oligosaccharides moieties, *Immunol. Lett.*, 8:273-277). This design
helps to preserve the total number of available binding sites and renders the attached
antibodies less immunogenic to F_C receptor-bearing cells such as macrophages.
10 Spacers other than the avidin-biotin bridge can also be used, as are known in the art.
For example, Staphylococcal protein A can be coated on the nanospheres for binding
the F_C portions of immunoglobulin molecules to the nanospheres.

15 Cross-linking can be used to stabilize nanospheres. This is particularly useful
for protein-based nanospheres, such as those made of gelatin. The rate of nanosphere
degradation and nucleic acid release can be designed *a priori* by varying the extent of
cross-linking. Increased cross-linking yields increased stability of the nanosphere. The
loading level of nucleic acid can be as high as 30% (w/w), with an encapsulation
efficiency of >95%.

20 Cross-linking of linking molecules or targeting ligands to the nanosphere is
used to promote the stability of the nanosphere as well as to covalently affix the linking
molecule or targeting ligand to the nanosphere. The degree of cross-linking directly
affects the rate of nucleic acids release from the microspheres. Cross-linking can be
accomplished using glutaraldehyde, carbodiimides such as EDC (1-ethyl-3-(3-
25 dimethylaminopropyl)-carbodiimide, DCC (N,N'-dicyclohexylcarbodiimide), carboxyls
(peptide bond) linkage, bis (sulfosuccinimidyl) suberate, dimethylsuberimidate, etc.

30 Targeting ligands according to the present invention are any molecules which
bind to specific types of cells in the body. These may be any type of molecule for
which a cellular receptor exists. Preferably the cellular receptors are expressed on
specific cell types only. Examples of targeting ligands which may be used are
hormones, antibodies, cell-adhesion molecules, saccharides, drugs, and
neurotransmitters.

5 The nanospheres of the present invention have good loading properties. Typically, following the method of the present invention, nanospheres having at least 10
10 5% (w/w) nucleic acids can be achieved. Preferably the loading is greater than 10 or 15% nucleic acids. Often nanospheres of greater than 20 or 30%, but less than 40 or 50% nucleic acids can be achieved. Typically loading efficiencies of nucleic acids into nanospheres of greater than 95% can be achieved.

15 The method of the present invention involves the coacervation of polymeric cations and nucleic acids. Because this process depends on the interaction of the positively charged polymeric cations and the negatively charged nucleic acids it can be considered as a complex coacervation process. However, sodium sulfate (or ethanol) induces the coacervation reaction by inducing a phase transition, and therefore it could also be considered as a simple coacervation reaction. Nucleic acids are present in the coacervation mixture at a concentration of between 1 ng/ml to 500 µg/ml. Desirably the nucleic acids are at least about 2-3 kb in length, and may range up to 10, 20, or 50 kb. Sodium sulfate is present at between 5 and 100 mM. Gelatin or other polymeric cation is present at between about .01 and 7%, preferably between 2 and 5% (w/v), in the coacervation mixture. Typically, about ten-fold higher amounts of amino acid-based polymers are required than carbohydrate based polymers. Thus gelatin is typically used at 1-5%, while chitosan is typically used at 0.01 to 0.05%. Using chitosan, suitable concentrations of nucleic acids are between 0.002% and 0.008%.

20 An attractive nanosphere delivery system requires a delicate balance among factors such as the simplicity of preparation, cost effectiveness, nucleic acids loading level, controlled release ability, storage stability, and immunogenicity of the components. The gene delivery system described here may offer advantages compared to other particulate delivery systems, including the liposomal system. The problems of instability, low loading level, and controlled release ability are better resolved with the polymeric nanosphere systems. Gelatin has received increasing biologic use ranging from surgical tissue adhesive (Weinschelbaum, et al., 1992, Surgical

5 treatment of acute type A dissecting aneurysm with preservation of the native aortic valve and use of biologic glue. Follow-up to 6 years, *J. Thorac. Cardiovasc. Surg.*,
10 130:369-74) to quantitative immunohistochemical assays (Izumi, et al., 1990, Novel
gelatin particle agglutination test for serodiagnosis of leprosy in the field, *J. Clinical
Microbiol.*, 28:525-9) and as drug delivery vehicle (Tabata, et al., 1991, Effects of
recombinant alpha-interferon-gelatin conjugate on in vivo murine tumor cell growth,
15 *Cancer Res.*, 51:5532-8), due to its biocompatibility and enzymatic degradability *in
vivo*. Compared to other synthetic polymeric systems, such as the extensively studied
synthetic polymeric nanospheres, complex coacervation requires neither contact with
organic solvents nor heat. It is also particularly suitable for encapsulating bio-
macromolecules such as nucleic acids not only through passive solvent capturing but
also by direct charge-charge interactions.

20 Unlike viral vectors, which cannot deliver genes larger than 10 kb, the
nanosphere delivery system of the present invention does not have such size
limitations. Nucleic acid molecules of greater than about 2 kb can be used, and
nucleic acid molecules even from 10 to 50 kb may be used.

25 In general, the range of possible targets is dependent on the route of injection,
e.g., intravenous or intraarterial, subcutaneous, intra-peritoneal, intrathecal, etc. For
systemic injections, the specificity of this delivery system is affected by the accessibility
of the target to blood borne nanospheres, which in turn, is affected by the size range
of the particles. Size of the particles is affected by temperature, component
concentration, and pH in the coacervation mixture. The particles can also be size-
fractionated, *e.g.*, by sucrose gradient ultracentrifugation. Particles with size less than
30 150 nanometers can access the interstitial space by traversing through the
fenestrations that line most blood vessels walls. Under such circumstances, the range
of cells that can be targeted is extensive. An abbreviated list of cells that can be
targeted includes the parenchymal cells of the liver sinusoids, the fibroblasts of the

5 connective tissues, the cells in the Islets of Langerhans in the pancreas, the cardiac myocytes, the Chief and parietal cells of the intestine, osteocytes and chondrocytes in the bone, keratinocytes, nerve cells of the peripheral nervous system, epithelial cells of the kidney and lung, Sertoli cells of the testis, etc. The targets for particles with sizes greater than 0.2 microns will be confined largely to the vascular compartment. Here,
10 the targetable cell types include erythrocytes, leukocytes (i.e. monocytes, macrophages, B and T lymphocytes, neutrophils, natural killer cells, progenitor cells, mast cells, eosinophils), platelets, and endothelial cells.

15 For subcutaneous injections, the targetable cells include all cells that resides in the connective tissue (e.g., fibroblasts, mast cells, etc.), Langerhans cells, keratinocytes, and muscle cells. For intrathecal injections, the targetable cells include neurons, glial cells, astrocytes, and blood-brain barrier endothelial cells. For intraperitoneal injection, the targetable cells include the macrophages and neutrophils.

20 Carbohydrate-based nanospheres such as those made using chitosan offer many advantages. Cross-linking is not required. In addition, a targeting ligand is not required, although it can be used. Although applicants do not wish to be bound by any particular theory, it is postulated that cells have a receptor to which chitosan binds. The concentration of DNA required in the coacervation mix using chitosan is about half of that required using gelatin. In addition, the concentration of chitosan required is about one tenth that required for making gelatin nanospheres. Chitosan based
25 nanospheres can be freeze dried and are storage stable.

Because chitosan-based nanospheres need not be cross-linked or reacted with targeting ligands, they can be readily used after formation without the need for extensive post-synthesis purifications. Elimination of this post-synthesis processing permits the direct use of freshly made coacervates to transfect cells. An additional contrast between chitosan- and gelatin-based nanospheres is the effect of chloroquine on transfection efficiencies. In the gelatin system, chloroquine improves the transfection efficiency. However, in the chitosan system, chloroquine does not improve the transfection efficiency. The size of the nanospheres is believed to be
30

5 critical for efficient cellular delivery. Typically the nanospheres are less than 4, 3, 2, or even 1 μm . Most preferably the solid particles are between 200 and 300 nm.

Examples:

Example 1

10 *Matrix Materials:* Gelatin (60 bloom, type A from porcine skin), chondroitin 4-sulfate, glutaraldehyde (25%, grade 1), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC hydrochloride), and ultra-pure sucrose were purchased from Sigma Chemical Co. (St. Louis, MO). Biotin LC hydrazide, and NeutrAvidin, and Coomassie protein assay reagents were from Pierce (Rockford, IL). Centricon microconcentrators were from Amicon (Beverly, MA).

15 *Monoclonal antibodies:* mAb PLM-2, a BALB/c mouse anti-porcine LFA-1 (IgG_{1b}) which also cross reacts with murine LFA-1, was isolated and purified as previously described (Hildreth, et al., 1989, Monoclonal antibodies against porcine LFA-1: species cross-reactivity and functional effects of b-subunit-specific antibodies, *Molec. Immunol.*, 26:883-895). IB-4B, a rat anti-mouse LAMP-1 ascite fluid and a mouse anti-human CD44 mAb were isolated as previously described (de Wet, et al., 1987, Firefly luciferase gene: structure and expression in mammalian cells, *Mol. & Cell. Biol.*, 7:725-37). CHA is a IgG₁ that does not recognize any known *in vivo* mouse epitopes (Hybritech Inc., San Diego, CA). Affinity-purified FITC and Texas Red-labeled polyclonal anti-rat IgGs were obtained from Sigma.

25 *Genes:* Two genes were used to demonstrate the feasibility of this delivery system. The LAMP-a cDNA is a 6.4 kb circular supercoiled plasmid cDNA with a mouse LAMP-1 gene (2.4 kb) inserted into an Invitrogen plasmid cDNA with a CMV promoter (Guaarnieri, et al., 1993, *J. Biol. Chem.*, 268:1941). Detection of LAMP-1 expression was done by staining cells with anti-LAMP-1 mAb and with secondary anti-IgG mAb conjugated with Texas Red. The gene coding for luciferase enzyme is widely used in cell biology for the study of gene expression because of the high sensitivity of the assay, its simplicity, and low cost. In addition, the enzyme is a good reporter of gene expression because it is a cytosolic protein that does not require post-

30

5 translational processing for enzymatic activity (de Wet, et al., 1987, Firefly luciferase
gene: structure and expression in mammalian cells, *Mol. & Cell. Biol.*, 7:725-37;
Wood, et al., 1989, Introduction to beetle luciferases and their applications, *J. of
Biolumin. & Chemilum.*, 4:289-301). The presence of luciferase can be readily
detected by an enzymatic reaction that involve the oxidation of beetle luciferin with
10 concomitant production of a photon (in the form of chemiluminescence.) The assay
was carried out using an assay kit purchased from Promega Corp. (Madison, WI).

15 *Synthesis of microspheres:* A detailed schematic diagram for the synthesis of
the gelatin-DNA coacervates is shown in Figure 1. All concentrations described are
final concentrations in the reaction mixture set at 67°C unless otherwise stated.
Gelatin/plasmid DNA nanospheres coated with avidin were synthesized by first
preparing a 3.5 mg/ml solution of plasmid DNA encoding a lysosomal associated
membrane protein-1 (LAMP-1) (6.7 Kb, circular supercoiled) in 42 mM sodium
sulfate (Na_2SO_4). Coacervation was initiated by the addition of gelatin (5%) to the
DNA/ Na_2SO_4 solution at equal volume while vortexing at high speed for 1 minute.
20 Coencapsulation of drugs and other agents can be achieved by adding directly to the
DNA/ Na_2SO_4 solution before initiating coacervation with gelatin. Avidin (5 mg/ml)
was added to the microsphere suspension at a final concentration of 75 ug avidin/ml
microsphere solution. The microspheres mixture was layered onto a layer of 70%
sucrose (w/v) and centrifuged at 6,000 x g for 4 minutes (Brinkman Instruments Inc.,
25 Westbury, NY, model L8-75). Microsphere fractions recovered from the sucrose layer
was diluted 5-fold with water then cross-linked with glutaraldehyde (12.5 mM final
concentration) for 10 minutes at room temperature. Unreacted glutaraldehyde was
quenched by adding ethanolamine (1 M) for 10 minutes. The microspheres were
dialyzed by sucrose centrifugation as described above.

30 *Attachment of biotinylated mAbs to avidin-coated microspheres:* 30 ug of
antibodies (biotinylated according to established procedures (O'Shannessy, et al.,
1984, A novel procedure for labeling immunoglobulins by conjugation to
oligosaccharides moieties, *Immunol. Lett.*, 8:273-277)) was added to 1 ml of avidin-

5 coated microspheres suspension (11 mg/ml) for 1 hour with gentle agitation. Unbound mAb was removed from microspheres by dialysis.

10 *Characterization of microsphere and binding performance:* DNA loaded microspheres exhibited polymorphic colloid shape with a polydispersed particle size of less than 3 microns as determined by light microscopy. Purified microspheres were stable for at least one month without appreciable degradation. The loading level for LAMP-1 plasmid DNA was 20% (w/w). The encapsulation efficiency was typically >95%. The mobility of the free LAMP-1 DNA and the released DNA (from the microsphere) in 1% agarose gel electrophoresis were identical (Fig. 2), suggesting that the encapsulated DNA was released in its original form. Release rate of the cDNA from the microspheres was dependent on the cross-linking density and on the enzyme level (Figure 4). Sustained release of up to weeks can be readily obtained.

15 We tested the ability of the LAMP-1 DNA loaded microspheres to bind and subsequently transfect a human histiocytic lymphoma cell line (U937) in tissue culture. When coated with either anti-LFA or anti-CD44 monoclonal antibody (both protein targets were expressed in high amount of U937 cell surface), expression 20 LAMP-1 protein was detected by day 3 (Fig. 4A, fluorescent granules) when stained with antibodies recognizing LAMP-1. The staining pattern of U937 cells incubated with LAMP-1 microspheres was identical to the calcium phosphate method of transfection (Figure 4B). Microspheres that were either coated with avidin or non-specific CHA mAb showed no granular staining patterns, and were identical to 25 untreated cells (Fig. 4C).

30 Using flow cytometry, we showed that the expression of LAMP-1 was detected in up to 5% of U937 cells in culture (Figure 5). None of the controls -- blank microspheres, microspheres with cDNA but no antibodies, microspheres with cDNA and coated with a mismatched anti-P-glycoprotein antibody (MRK-Msp.), and free cDNA at a concentration six time higher than entrapped in the microspheres -- showed any evidence of transfection. The efficiency of transfection appears to be dose-responsive. In general, the transfection efficiency of this particular gene and cell type

5 is comparable between the proposed microspheric delivery system (1-10%) and the calcium phosphate precipitation method (2-15%). Figure 6 demonstrates the concept in a different cell type using a different monoclonal antibody. Again, free cDNA could not transfect the cells. Eventually the LAMP-1 expression disappeared after several passages. Positive results were also obtained for the luciferase reporter gene system.
10 Transfection was clearly detected by measurement of luciferase enzymatic activity, in 293s cells incubated with luciferase gene-loaded microspheres.

Example 2

The general concept of synthesizing the DNA nanospheres is shown in Figure 7.

15 DNA-gelatin nanospheres were synthesized by vortexing 100 ml of a solution containing gelatin (5% w/v in distilled water) and 4 mM chloroquine with 100 ml of a solution containing 0.2 mg/ml plasmid DNA and 4.3 mM sodium sulfate (Na_2SO_4) at 55°C for one minute. Nanospheres without chloroquine were synthesized similarly except with a higher Na_2SO_4 concentration (45 mM). The unreacted components were removed by centrifuging the mixture in a 100 ml sucrose layer (55% w/w) at 40,000 x g for 7 minutes. The sucrose fraction containing the nanospheres was diluted with water to 200 ml, then crosslinked and conjugated with
20 transferrin by adding the nanosphere and transferrin solution (20 mg) to 22 ml of a 0.2 M MES buffer solution, pH 4.5, containing 0.1 mg/ml of (1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride) (EDC). The reaction was carried out in room temperature for 30 minutes, then quenched by addition of glycine reaching a 0.2 M final concentration. Crosslinking was also achieved by
25 reaction with various concentrations of glutaraldehyde for 10 min. DNA-chitosan nanospheres were prepared similarly with the exception that the chitosan solution was diluted to 0.02% (w/v, pH 5.5 in 5 mM NaAc-HOAc).

Example 3

The general concept of synthesizing DNA nanospheres is shown in Figure 7. Microparticulate coacervates of chitosan or gelatin-DNA complexes formed as a result of Na_2SO_4 -induced desolvation

5 of the local water environment of the polyelectrolytes. Synthesis of the nanospheres
was optimized with respect to salt concentration, pH, temperature, and reactant
concentrations, as shown in the three- phase diagram of Figure 14. At 55°C, pH
10 5.5, and a sodium sulfate concentration of 50 mM, phase separation of particulate
chitosan-DNA complexes occurred at the concentration range of 0.005 to 0.02 %
SEM in Figure 15, nanospheres in the range of 200-320 nm were formed.

15 The solid nanospheres protect the DNA from enzymatic degradation (Figure
20 16). Stability studies of the DNA-chitosan nanospheres were conducted in 10% fetal
bovine serum (FBS), where the nuclease decomposed the DNA. Gel electrophoretic
mobility analysis indicated naked DNA incubated for 15 minutes in the serum showed
clear indication (Lane 5), whereas the DNA in the nanosphere remained intact (Lanes
15 6 and 7). Even at a 5-fold higher nuclease concentration of 0.5 ug/ml, there was still
no sign of degradation (Lanes 8 and 9).

20 The cytotoxicity of chitosan was compared to other polycationic gene carriers
(Figure 17). Chitosan was nontoxic at least up to a concentration of 200 ug/ml. The
DNA-chitosan nanospheres containing the GFP DNA transfected the 293 cells in a
dose-responsive manner (Figure 18). Uptake of the DNA-chitosan nanospheres was
rapid as demonstrated by FACScan analysis (Figure 19). Almost 100% of cells have
taken up the nanospheres in 2 hours of incubation, displaying saturable kinetics.

25 To allow lyophilization without aggregation, nanospheres were derivatized
according to the chemical scheme shown in Figure 21. One mL of DNA-chitosan
nanospheres suspension containing 50 mg of pcDNA was mixed with 5 mL of DSS
solution (10 mM), 10 mL of α -maleimidyl- ω -N-hydroxysuccinimidyl poly(ethylene
glycol) solution (NHS-PEG-MAL, MW 2000, 5 mM), 20 mL of succinimidyl
30 succinamide of methoxy poly(ethylene glycol) solution (SSA-PEG, MW 5000, 10
mM) and 100 mL of PBS buffer under vortexing. The mixture was stirred at room
temperature for 30 min before 50 mL of 1 M glycine was added to quench the
reaction, followed by adding 250 mg of transferrin modified with sulphydryl group (free

5 sulphydryl groups were introduced into transferrin by 2-iminothiolane reaction, modification degree was 3~6 per transferrin). After reaction for 2 hours at room temperature, the mixture was ultracentrifuged at 50,000g for 20 min in a 55% sucrose gradient. The nanospheres isolated were lyophilized directly. Conjugation of PEG5000 to the surface of the nanospheres minimized any aggregation in solution.
10 These nanospheres could also be lyophilized without any anti-caking agent and easily resuspended. Transfection efficiency of the nanospheres was not affected by this PEG derivatization (Figure 20). Neither was it affected by storage in sucrose solution or in the lyophilized state.

15 Comparison of *in vivo* transfection efficiency was conducted by injecting gelatin nanospheres containing the LacZ plasmid (1 mg total DNA), DNA-Lipofectamine complex (1 mg total DNA), naked plasmid DNA (1 mg), or 5×10^{10} viral particles of AAV-LacZ suspended in 20 ml into the exposed tibialis anterior muscle bundles of six-week old BALB/c mice. One and three weeks later, the muscle was isolated, homogenized, and the reporter gene expression determined by an assay kit (Galacto-Light) supplied by Tropix (Bedford, MA). Injection of gelatin nanospheres containing 1 mg of the LacZ gene into the tibialis muscle bundle of mice produced β -gal expression for at least 21 days (Figure 22). The level for an equivalent dose of naked DNA was 10-30 fold lower at day 7, and declined to background level by day 21. In contrast to their relative performance *in vitro*, the Lipofectamine complexes were not as efficient as the nanospheres. The expression level at day 7 was even lower than that of naked DNA. By gross observation, there was acute inflammatory response in the muscle tissue treated by the Lipofectamine complexes, which might account for the poor result. The AAV vector was the most efficient, eliciting a β -gal expression of 50-100 times higher than that of the nanospheres at day 7, and the level increased 6-12 fold further at day 21, probably due to viral replication.
20
25
30

Nanospheres synthesized by salt-induced complex coacervation of cDNA and polycations such as gelatin and chitosan are efficient gene delivery vehicles. DNA-nanospheres in the size range of 200-750 nm could transfet a variety of cell

5 lines. Although the transfection efficiency of the nanospheres was typically lower than
that of Lipofectamine and calcium phosphate controls in cell culture, the β -gal
expression in muscle of BALB/c mice was higher and more sustained than that
achieved by naked DNA and Lipofectamine complexes. This gene delivery system has
several attractive features: 1) ligands can be conjugated to the nanosphere to stimulate
10 receptor-mediated endocytosis; 2) lysosomolytic agents can be incorporated to reduce
degradation of the DNA in the endosomal and lysosomal compartments; 3) other
bioactive agents or multiple plasmids can be co-encapsulated; 4) bioavailability of the
DNA can be improved because of protection from serum nuclease degradation by the
matrix; 5) the nanosphere is stable in plasma electrolytes, and can be lyophilized for
15 storage without loss of bioactivity.

5

CLAIMS

1. A solid nanosphere of less than 3 μm for gene delivery to cells, comprising a polymeric cation and a polyanion, wherein the polyanion consists of nucleic acids, wherein the polymeric cation is not polylysine.

10

2. The nanosphere of claim 1 wherein the polymeric cation is a carbohydrate.

3. The solid nanosphere of claim 2 wherein the polymeric cation is chitosan.

4. The nanosphere of claim 1 wherein said nanosphere comprises greater than 5% (w/w) nucleic acids.

15

5. The nanosphere of claim 1 wherein said nanosphere comprises greater than 20% (w/w) nucleic acids.

6. The nanosphere of claim 1 wherein said nucleic acids comprise a gene of 2-20 kb.

7. A method of forming solid nanospheres for gene delivery to specific target cells, comprising the step of:

20

forming nanospheres of less than 3 μm by coacervation of nucleic acids and a polymeric cation which is not polylysine.

8. The method of claim 7 wherein the polymeric cation is a carbohydrate.

9. The method of claim 8 wherein the coacervation is performed in the presence of sodium sulfate.

25

10. The method of claim 8 wherein the polymeric cation is chitosan.

11. The method of claim 8 wherein the polymeric cation is present at a concentration of about 0.01-7% in the step of coacervation.

12. The method of claim 8 wherein the nucleic acids are present in a concentration of 1 ng/ml to 500 $\mu\text{g}/\text{ml}$ in the step of coacervation.

30

13. The method of claim 8 wherein the concentration of sodium sulfate is between about 5 and 100 mM in the step of coacervation.

14. A method for introducing genes into cells, comprising the steps of:

5 incubating (a) cells to be transfected with (b) solid nanospheres of less than 3 μm comprising polymeric cationic molecules and nucleic acid molecules, whereby the cells are transfected with the nucleic acid molecules, wherein the polymeric cationic molecules are not polylysine.

10 15. The method of claim 14 wherein the polymeric cationic molecules are carbohydrates.


16. The method of claim 15 wherein the polymeric cationic molecules are chitosan.

17. The method of claim 15 wherein the nucleic acid is DNA.

18. The method of claim 15 wherein the nucleic acid is RNA.

15 19. The method of claim 14 wherein the cells are in culture.

20. The method of claim 14 wherein the cells are in an animal.

FIG. 1

* CIRCULAR, SUPERCOILED DOUBLE STRANDED PLASMID cDNA 6.8kb (LAMP-1) OR ~ 5.1kb (LUCIFERASE) 0.6-3.5 mg./ml IN H_2O .

** GELATIN (60 BLOOM, TYPE A FROM PORCINE SKIN) FRESHLY MADE.

2/22

FIG. 2

LAMP-1 Reaction cDNA Std. Mixture (0.5 µg)	LAMP-1 Reaction cDNA Std. Mixture (1.5 µg)
(Sup)	(Pellet)



FIG. 3A





FIG. 3B



4/22

FIG. 4B





FIG. 4D


FIG. 4C

FIG. 5



SUBSTITUTE SHEET (RULE 26)

6/22

FIG. 6**SUBSTITUTE SHEET (RULE 26)**




FIG. 7

SUBSTITUTE SHEET (RULE 26)

8/22




FIG. 8

SUBSTITUTE SHEET (RULE 26)

9/22






FIG. 9

SUBSTITUTE SHEET (RULE 26)

10/22

**SUBSTITUTE SHEET (RULE 26)**

II/22

FIG. 11**SUBSTITUTE SHEET (RULE 26)**

12/22




FIG. 12**SUBSTITUTE SHEET (RULE 26)**


FIG. 13

14/22


FIG. 14**SUBSTITUTE SHEET (RULE 26)**

15/22

Fig. 6



TEM: Scale Bar = 210 nm



SEM: Scale Bar = 356 nm

16/22

5/13/98

1. MVV marker
2. Plasmid
3. Nanospheres
4. Digested Nsp
5. Plasmid + DNase (0.1 µg)
6. Nsp + DNase (0.1 µg)
7. 6 + Digestion
8. Nsp + 0.5 µg DNase
9. 8 + Digestion




FIG. 17







FIG. 18


19/22

FIG. 19**SUBSTITUTE SHEET (RULE 26)**


20/22

FIG. 20


SUBSTITUTE SHEET (RULE 26)

FIG. 21

22/22

FIG. 22

SUBSTITUTE SHEET (RULE 26)





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48		A3	(11) International Publication Number: WO 98/01162 (43) International Publication Date: 15 January 1998 (15.01.98)
(21) International Application Number: PCT/US97/13116		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 July 1997 (09.07.97)			
(30) Priority Data: 60/021,408 9 July 1996 (09.07.96) US			
(71) Applicant: THE JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US).			
(72) Inventors: ROY, Krishnendu; Apartment 404, 3811 Canterbury Road, Baltimore, MD 21218 (US). MAO, Hai-Quan; Apartment C8, 334 Stevenson Lane, Towson, MD 21205 (US). TRUONG, Thomas; 2008 McElderry Street, Baltimore, MD 21205 (US). AUGUST, Thomas; 905 Poplar Hill Road, Baltimore, MD 21210 (US). LEONG, Kam, W.; 10242 Breconshire Road, Ellicot City, MD 21042 (US).			
(74) Agents: SHEA, Michael, J. et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).			
<p>Published <i>With international search report</i></p> <p>(88) Date of publication of the international search report: 14 May 1998 (14.05.98)</p>			
<p>(54) Title: GENE DELIVERY SYSTEM</p> <p>(57) Abstract</p> <p>A gene delivery system is made of enzymatically degradable polymeric cation and nucleic acid (DNA or RNA) nanospheres optionally with a linking moiety or a targeting ligand attached to the surface. The delivery system can be made by a simple method of coacervation. Targeting ligands can be attached to the nanosphere directly or via a linking moiety. The linkage design allows the attachment of any molecule onto the nanosphere surface including antibodies, cell adhesion molecules, hormones and other cell-specific ligands.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon			PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

INTERNATIONAL SEARCH REPORT

In Application No
PCT/US 97/13116

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	DATABASE WPI Section Ch, Week 9141 Derwent Publications Ltd., London, GB; Class B04, AN 91-299437 XP002052418 & JP 03 198 782 A (KURITA WATE IND KK), 29 August 1991 see abstract	1-20
X	---	1
X	WO 95 22963 A (MEDINOVA MED CONSULTING GMBH) 31 August 1995 see claims	
X	---	
X	WO 96 00295 A (UNIV JOHNS HOPKINS) 4 January 1996 see page 13, paragraph 3; claims see page 12, paragraph 1	1-20

	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

1

Date of the actual completion of the international search

19 January 1998

Date of mailing of the international search report

27.02.98

Name and mailing address of the ISA

European Patent Office, P.O. Box 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Berte, M

C (Continued) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation or document, with indication, where appropriate, of the relevant passages	Relevant to claim(s)
P,X	ROY, KRISHNENDU ET AL: "DNA - chitosan nanospheres: transfection efficiency and cellular uptake" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1997), 24TH, 673-674 CODEN: PCRMEY;ISSN: 1022-0178, 1997, XP002052412 see figures ---	1-20
P,X	MAO, H.-Q. ET AL: "DNA - chitosan nanospheres: derivatization and storage stability" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1997), 24TH, 671-672 CODEN: PCRMEY;ISSN: 1022-0178, 1997, XP002052413 see figures ---	1-20
X	MAO, H.-Q. ET AL: "DNA - chitosan nanospheres for gene delivery" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1996), 23RD, 401-402 CODEN: PCRMEY;ISSN: 1022-0178, 1996, XP002052414 see figure 1 ---	1-20
P,X	WALSH, S.M. ET AL: "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1997), 24TH, 75-76 CODEN: PCRMEY;ISSN: 1022-0178, 1997, XP002052415 see figures ---	1,4-7, 11-14
P,X	TRUONG-LE, VU L. ET AL: "Delivery of DNA vaccine using gelatin-DNA nanospheres" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1997), 24TH, 39-40 CODEN: PCRMEY;ISSN: 1022-0178, 1997, XP002052416 see figures ---	1,4-7, 11-14
E	WO 97 32572 A (PENN STATE RES FOUND ;MASSACHUSETTS INST TECHNOLOGY (US)) 12 September 1997 see claims 1,8,9,14,20,29 -----	1

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 97/13116

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos 14-20 because they relate to subject matter not required to be searched by this Authority, namely Although claims 14-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition
2. Claims Nos : because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically
3. Claims Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos .
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos

Remark on Protest

The additional search fees were accompanied by the applicant's protest
 No protest accompanied the payment of additional search fees

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9522963 A	31-08-95	AU 1947395 A CA 2184242 A EP 0740548 A HU 75469 A JP 9506109 T	11-09-95 31-08-95 06-11-96 28-05-97 17-06-97
WO 9600295 A	04-01-96	AU 2946295 A CA 2193954 A EP 0769063 A	19-01-96 04-01-96 23-04-97
WO 9732572 A	12-09-97	AU 2063197 A	22-09-97